CJC-1295 and Ipamorelin act on the growth hormone axis. This is a hormonal system regulated separately from testosterone. While there is a scientifically plausible reason to expect some interaction with sleep, no dedicated human study has measured testosterone levels or detailed sleep outcomes in individuals taking either compound. This article consolidates what is actually known on these subjects, briefly revisits claims regarding collagen and skin discussed more extensively elsewhere in this series, and then looks specifically at what a realistic hormonal activity schedule looks like for the first month.
The effect of CJC-1295 and Ipamorelin on testosterone levels
Growth hormone and testosterone are produced and regulated by two distinct hormonal control systems in the body. There is the growth hormone axis, on which CJC-1295 and ipamorelin act. And there is a separate hypothalamic-pituitary-gonadal axis that manages testosterone production. No published human studies show either peptide directly raising testosterone. A review focused on growth hormone stimulators as a potential adjunctive therapy in men with low testosterone described how these compounds could support body composition and certain symptoms associated with low testosterone, as an adjunct to standard testosterone therapy. However, this proposed benefit was framed as an indirect metabolic effect rather than a direct hormonal boost. The review's authors were clear that supporting clinical data remains limited [1].
Separately, the basic pharmacological studies of ipamorelin are worth noting for a related reason. It has specifically been shown not to significantly raise cortisol or ACTH, unlike some older growth hormone-releasing peptides. This demonstrates true selectivity for the growth hormone pathway. The same study, however, did not measure or report testosterone at all [2].
Given the complete lack of direct evidence, it would be inaccurate to describe any peptide as a testosterone-boosting compound. Any link between these peptides and testosterone remains theoretical and unproven by current research.
Effects of CJC-1295 and Ipamorelin on sleep quality
The proposed link between these peptides and sleep is based on a really well-established principle in general endocrinology. Growth hormone is naturally released in its largest pulses during deep, slow-wave sleep. This relationship has been documented for decades in sleep studies. As both CJC-1295 and ipamorelin are designed to enhance the release of growth hormone, this creates a scientifically sensible basis for expecting some interaction with sleep. This is likely the source of the common suggestion of dosing these compounds before bedtime.
However, no controlled trials identified in the reviewed literature for this series directly measured sleep onset, sleep stage duration, or subjective sleep quality in individuals using either compound. Claims of „sleep benefits” therefore remain an extrapolation from general growth hormone and sleep physiology, rather than a confirmed discovery specific to CJC-1295 or ipamorelin.
What is documented is the hormonal timing itself. CJC-1295 induces a sustained growth hormone increase lasting six days or longer following a single dose, with the body’s natural pulsatile rhythm preserved rather than replaced [3], [4]. Ipamorelin causes a rapid, short pulse peaking around 40 minutes after administration [5]. This timing information is important background, but in isolation does not establish an outcome regarding sleep quality.
Effects of CJC-1295 and Ipamorelin on Collagen and Skin
As discussed in more detail in an earlier article in this series, IGF-1 – a hormone that increases as a result of CJC-1295 and ipamorelin acting on growth hormone – has a genuine, documented role in stimulating collagen production. This has been demonstrated in laboratory studies of human skin fibroblasts, the cells responsible for building connective tissue [6]. These cell-level studies are justified and scientifically sound. However, they largely stem from studies using IGF-1 directly on cultured skin cells or local tissue, rather than from measuring actual skin or joint outcomes in humans where IGF-1 has been elevated systemically via a growth hormone-stimulating peptide.
No studies identified in this research series measured skin thickness, wrinkle depth, or connective tissue outcomes in humans using CJC-1295 or ipamorelin. Therefore, while the underlying cellular mechanism is plausible, claims of visible skin or joint benefits from these peptides remain an extrapolation rather than a demonstrated clinical outcome.
What to expect from CJC-1295 – the first month's effects
Based strictly on documented human hormonal kinetics, the first month of CJC-1295 use would be expected to unfold in a specific, trackable pattern. It's important to note that this describes the changes in hormonal levels as measured in a clinical trial setting, not the subjective or physical effects a person might necessarily notice day-to-day. In the primary human study, a single injection elicited a rise in growth hormone within hours, lasting for six days or longer. IGF-1, a more slowly rising, longer-lasting marker, took a bit longer to increase, but then remained elevated for nine to eleven days after that single dose alone [3].
With repeated dosing on a weekly or fortnightly schedule, given the compound's long half-life of approximately 5.8–8.1 days, studies have shown that IGF-1 levels continue to accumulate and remain above baseline for up to 28 days. The study authors specifically noted evidence of a cumulative effect. This means that each subsequent dose built upon the elevated levels from the previous one, rather than simply repeating an isolated spike [3].
Translating this into a picture of the first month: the early days after the first dose would, based on this hormonal data, be expected to show a rising growth hormone curve followed by a rising IGF-1 curve. A second, and possibly third, dose – if following a weekly or bi-weekly schedule similar to the trial – would be needed to achieve a type of sustained, cumulative IGF-1 elevation documented by day 28.
It is worth clearly repeating that this schedule describes blood hormone measurements from a specific clinical study in healthy adults. It does not describe or predict when an individual might notice any physical change, as no study tracked subjective or observable outcomes during the first month of use.
Limitations of current evidence
When it comes to testosterone, sleep, and claims about collagen and skin, the same pattern persists. Each is linked to a real, well-documented general physiological principle. However, none have been directly tested in a dedicated human study for CJC-1295 or ipamorelin measuring that specific outcome.
The hormonal schedule for the first month is the most concretely evidence-based section of this article. However, even it reflects data from blood tests from a controlled study, rather than a guide to subjective or visible effects.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. CJC-1295 and ipamorelin remain research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. No published human studies have directly measured testosterone levels, sleep quality, or skin outcomes in individuals using these compounds. The hormone schedule described herein reflects blood data from a specific clinical trial and does not anticipate individual physical or subjective effects.
References
[1] Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: The role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl. 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
[2] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[4] Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
[5] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[6] Hsieh, W.-J., Qiu, W.-Y., Percec, I., & Chang, T.-M. (2025). Insulin-like growth factor 1 (IGF-1) in hair regeneration: Mechanistic pathways and therapeutic potential. Current Issues in Molecular Biology, 47(9), Article 773. https://doi.org/10.3390/cimb47090773